Transparency Guidelines for Relationships between Corporate Activities and Patient Groups
This page provides information on the Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations.
- About JPMA
- About Pharmaceuticals
- Information from the Committee
Information from the Committee Top
- Code Compliance Promotion Committee
- Industry Policy Committee
- Distribution Appropriateness Committee
- Drug Evaluation Committee
- Quality Committee
- Biopharmaceutical Committee
- Regulatory Affairs Committee
- Intellectual Property Committee
- Research and Development Committee
- International Committee
- Public Relations Committee
- Patient Organization Collaboration Promotion Committee
- ICH Project
- APAC Project
- Pharmaceutical Counseling and Response Review Committee
- Environmental Issues Review Committee
- Newsletter
- Newsroom
- The Office of Pharmaceutical Industry Research
- For Patients and the Public (About Pharmaceuticals)
-
Information from the Committee
- Code Compliance Promotion Committee
- Industry Policy Committee
- Distribution Appropriateness Committee
- Drug Evaluation Committee
- Quality Committee
- Biopharmaceutical Committee
- Regulatory Affairs Committee
- Intellectual Property Committee
- Research and Development Committee
- International Committee
- Public Relations Committee
- Patient Organization Collaboration Promotion Committee
- ICH Project
- APAC Project
- Pharmaceutical Counseling and Response Review Committee
- Environmental Issues Review Committee
- About JPMA
- Policies and Activities
-
Voluntary Standards
- Charter of Conduct
- JPMA Code of Practice
- Transparency Guidelines for Relationships between Corporate Activities and Medical Institutions
- Transparency Guidelines for Relationships between Corporate Activities and Patient Groups
- Guidelines for the Preparation of Product Information Summaries, etc. for Ethical Drugs (Abbreviated name: Preparation Guidelines)
- Clinical Research
- Basic Principles and Action Guidelines on Biodiversity
- Guidelines for Proper Competition at Japan Pharmaceutical Manufacturers Association Meetings
- Guideline for the Promotion of the Industry Vision 2035
- Newsroom
-
The Office of Pharmaceutical Industry Research
- Social Media Policy
- Website Terms of Use